迈克生物：公司交叉配血质控品获得医疗器械注册证

Core Viewpoint - The company announced that its cross-matching quality control product has received a medical device registration certificate from the National Medical Products Administration, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The new product is designed for use with the company's anti-human globulin (anti-IgG+C3d) testing card and is intended for quality control in manual and fully automated blood type analysis systems [1] - The product is specifically for clinical testing and is not intended for blood source screening [1] Group 2: Market Impact - The registration certificate for the new product is expected to positively influence the company's market expansion and future operations [1] - The actual sales performance of the registered product will depend on future marketing efforts, and the impact on the company's future revenue remains unpredictable [1]